Research ExplorerPublicationsAnalysis of posaconazole as oral antifungal prophylaxis in p...

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.

Standard

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. / Döring, Michaela; Müller, Carsten; Johann, Pascal-David; Erbacher, Annika; Kimmig, Astrid; Schwarze, Carl-Philipp; Lang, Peter; Handgretinger, Rupert; Müller, Ingo.

In: BMC INFECT DIS, Vol. 12, 2012, p. 263.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Döring, M, Müller, C, Johann, P-D, Erbacher, A, Kimmig, A, Schwarze, C-P, Lang, P, Handgretinger, R & Müller, I 2012, 'Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.', BMC INFECT DIS, vol. 12, pp. 263. https://doi.org/10.1186/1471-2334-12-263

APA

Döring, M., Müller, C., Johann, P-D., Erbacher, A., Kimmig, A., Schwarze, C-P., Lang, P., Handgretinger, R., & Müller, I. (2012). Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC INFECT DIS, 12, 263. https://doi.org/10.1186/1471-2334-12-263

Vancouver

Döring M, Müller C, Johann P-D, Erbacher A, Kimmig A, Schwarze C-P et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC INFECT DIS. 2012;12:263. https://doi.org/10.1186/1471-2334-12-263

Bibtex

@article{d4e78361c2754cd3999cd52a27ab6cce,
title = "Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.",
abstract = "Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk of acquiring fungal infections. Antifungal prophylaxis shortly after transplantation is therefore indicated, but data for pediatric patients under 12 years of age are scarce. To address this issue, we retrospectively assessed the safety, feasibility, and initial efficacy of prophylactic posaconazole in children.",
keywords = "Humans, Male, Female, Treatment Outcome, Child, Child, Preschool, Infant, Retrospective Studies, *Stem Cell Transplantation, *Immunocompromised Host, Antifungal Agents/*administration & dosage/adverse effects, Chemoprevention/adverse effects/*methods, Mycoses/*prevention & control, Triazoles/*administration & dosage/adverse effects, Humans, Male, Female, Treatment Outcome, Child, Child, Preschool, Infant, Retrospective Studies, *Stem Cell Transplantation, *Immunocompromised Host, Antifungal Agents/*administration & dosage/adverse effects, Chemoprevention/adverse effects/*methods, Mycoses/*prevention & control, Triazoles/*administration & dosage/adverse effects",
author = "Michaela D{\"o}ring and Carsten M{\"u}ller and Pascal-David Johann and Annika Erbacher and Astrid Kimmig and Carl-Philipp Schwarze and Peter Lang and Rupert Handgretinger and Ingo M{\"u}ller",
year = "2012",
doi = "10.1186/1471-2334-12-263",
language = "English",
volume = "12",
pages = "263",
journal = "BMC INFECT DIS",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.

AU - Döring, Michaela

AU - Müller, Carsten

AU - Johann, Pascal-David

AU - Erbacher, Annika

AU - Kimmig, Astrid

AU - Schwarze, Carl-Philipp

AU - Lang, Peter

AU - Handgretinger, Rupert

AU - Müller, Ingo

PY - 2012

Y1 - 2012

N2 - Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk of acquiring fungal infections. Antifungal prophylaxis shortly after transplantation is therefore indicated, but data for pediatric patients under 12 years of age are scarce. To address this issue, we retrospectively assessed the safety, feasibility, and initial efficacy of prophylactic posaconazole in children.

AB - Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk of acquiring fungal infections. Antifungal prophylaxis shortly after transplantation is therefore indicated, but data for pediatric patients under 12 years of age are scarce. To address this issue, we retrospectively assessed the safety, feasibility, and initial efficacy of prophylactic posaconazole in children.

KW - Humans

KW - Male

KW - Female

KW - Treatment Outcome

KW - Child

KW - Child, Preschool

KW - Infant

KW - Retrospective Studies

KW - Stem Cell Transplantation

KW - Immunocompromised Host

KW - Antifungal Agents/administration & dosage/adverse effects

KW - Chemoprevention/adverse effects/methods

KW - Mycoses/prevention & control

KW - Triazoles/administration & dosage/adverse effects

KW - Humans

KW - Male

KW - Female

KW - Treatment Outcome

KW - Child

KW - Child, Preschool

KW - Infant

KW - Retrospective Studies

KW - Stem Cell Transplantation

KW - Immunocompromised Host

KW - Antifungal Agents/administration & dosage/adverse effects

KW - Chemoprevention/adverse effects/methods

KW - Mycoses/prevention & control

KW - Triazoles/administration & dosage/adverse effects

U2 - 10.1186/1471-2334-12-263

DO - 10.1186/1471-2334-12-263

M3 - SCORING: Journal article

VL - 12

SP - 263

JO - BMC INFECT DIS

JF - BMC INFECT DIS

SN - 1471-2334

ER -